Aster DM Healthcare (ASTERDM) M&A Announcement summary

Deal rationale and strategic fit

• Merger creates one of the top three hospital chains in India, expanding reach to 38 hospitals and over 10,150 beds across 27 cities and nine states, with minimal overlap and a strong presence in South and Central India.

• The combined entity leverages Aster's expertise, Quality Care's strong non-metro presence, and four major brands, forming a holistic healthcare ecosystem spanning hospitals, clinics, labs, and pharmacies.

• Strategic alignment aims to bridge healthcare gaps, drive growth through facility upgrades, and enter new geographies via greenfield and brownfield projects, targeting ~13,300 beds by FY27.

• Backed by Blackstone, providing global expertise, financial strength, and access to capital.

Financial terms and conditions

• Aster valued at 36.6x FY24 EV/EBITDA, 45% higher than QCIL's 25.2x; post-merger shareholding: Aster shareholders 57.3%, QCIL shareholders 42.7%.

• Aster Promoters and Blackstone will hold 24% and 30.7% in the merged entity, with the rest held by public and QCIL shareholders.

• The merger is cash-neutral and expected to be EPS-accretive from the first full year.

• Aster will acquire a 5% stake in QCIL ahead of the merger via share issuance, with the rest completed through a share swap at the agreed ratio.

• Post-merger, total shares outstanding will increase from 50 crore to 87.16 crore.

Synergies and expected cost savings

• Near-term synergies are expected to result in a 10–15% EBITDA upside, with revenue growth, supply chain efficiencies, and integrated doctor model.

• Combined entity targets 25% EBITDA margin within three to four years, driven by cost and revenue synergies and brownfield expansions.

• Resource optimization, shared best practices, and enhanced ability to attract and retain medical talent will streamline operations.